{"id":47641,"date":"2022-08-25T02:01:36","date_gmt":"2022-08-25T00:01:36","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/biocytogen-expands-partnership-with-merck\/"},"modified":"2022-08-25T02:01:36","modified_gmt":"2022-08-25T00:01:36","slug":"biocytogen-expands-partnership-with-merck","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/biocytogen-expands-partnership-with-merck\/","title":{"rendered":"Biocytogen Expands Partnership with Merck"},"content":{"rendered":"
\n

BEIJING & DARMSTADT, Germany–(BUSINESS WIRE)–#License<\/a>–Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”) entered into a global licensing agreement with Merck for the use of Biocytogen\u2019s RenMice\u2122<\/sup> platform. Under the terms of the agreement, Merck will have full access to Biocytogen\u2019s RenMice\u2122 <\/sup>platform <\/sup>to discover and develop fully human antibody therapeutics for an unlimited number of drug targets. Merck will be responsible for all clinical development, manufacturing, and commercialization, and will provide Biocytogen with development and regulatory milestone payments. The official agreement was reached after an initial evaluation period.\n<\/p>\n

<\/a><\/p>\n

\nDr. Yuelei Shen, Founder, Chairman and CEO of Biocytogen, said, \u201cThis agreement provides Merck with one of the most advanced fully human antibody discovery platforms. We are pleased that Merck recognized the potential of our RenMice\u2122 platform to accelerate antibody development for novel and challenging targets.\u201d\n<\/p>\n

\nAbout Biocytogen<\/b>\n<\/p>\n

\nBiocytogen Pharmaceuticals (Beijing) Co., Ltd. is a global biotechnology company that drives the research and development of novel antibody-based therapeutics. The company has streamlined the drug development process through the use of RenMice\u2122 <\/sup>for fully human antibody discovery, in vivo<\/i> drug efficacy screening platforms and strong clinical development expertise. Biocytogen\u2019s RenMice\u2122<\/sup> HiTS Platform<\/a> aims to develop novel antibody drugs with first-in-class and\/or best-in-class potential for more than 1000 targets, and has resulted in collaborations with dozens of partners worldwide. The company’s pipeline includes 12 core products; two products are in phase II MRCTs and two products are in phase I. Headquartered in Beijing, Biocytogen has branches in Haimen Jiangsu, Shanghai, Boston, USA and Heidelberg, Germany. For more information, visit www.biocytogen.com<\/a>.\n<\/p>\n

\nAbout Merck<\/b>\n<\/p>\n

\nMerck, a leading science and technology company, operates across healthcare, life science and electronics. Around 60,000 employees work to make a positive difference to millions of people\u2019s lives every day by creating more joyful and sustainable ways to live. From advancing gene editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices \u2013 the company is everywhere. In 2021, Merck generated sales of \u20ac 19.7 billion in 66 countries.\n<\/p>\n

\nScientific exploration and responsible entrepreneurship have been key to Merck\u2019s technological and scientific advances. This is how Merck has thrived since its founding in 1668. The founding family remains the majority owner of the publicly listed company. Merck holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the business sectors of Merck operate as EMD Serono in healthcare, MilliporeSigma in life science, and EMD Electronics.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nPlatform Licensing:
\n
Li Hui
\n
info@biocytogen.com<\/a>\n<\/p>\n

\nMedia:
\n
Jenna Frame
\n
jframe@biocytogen.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

BEIJING & DARMSTADT, Germany–(BUSINESS WIRE)–#License–Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”) entered into a global licensing agreement with Merck for the use of Biocytogen\u2019s RenMice\u2122 platform. Under the terms of the agreement, Merck will have full access to Biocytogen\u2019s RenMice\u2122 platform to discover and develop fully human antibody therapeutics for an unlimited number of drug targets. … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-47641","6":"format-standard","7":"category-industry"},"yoast_head":"\nBiocytogen Expands Partnership with Merck - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/biocytogen-expands-partnership-with-merck\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Biocytogen Expands Partnership with Merck - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"BEIJING & DARMSTADT, Germany–(BUSINESS WIRE)–#License–Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”) entered into a global licensing agreement with Merck for the use of Biocytogen\u2019s RenMice\u2122 platform. Under the terms of the agreement, Merck will have full access to Biocytogen\u2019s RenMice\u2122 platform to discover and develop fully human antibody therapeutics for an unlimited number of drug targets. ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/biocytogen-expands-partnership-with-merck\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-08-25T00:01:36+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220824005289\/en\/1552165\/21\/Biocytogen%27s_LOGO.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/biocytogen-expands-partnership-with-merck\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/biocytogen-expands-partnership-with-merck\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Biocytogen Expands Partnership with Merck\",\"datePublished\":\"2022-08-25T00:01:36+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/biocytogen-expands-partnership-with-merck\\\/\"},\"wordCount\":431,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/biocytogen-expands-partnership-with-merck\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220824005289\\\/en\\\/1552165\\\/21\\\/Biocytogen%27s_LOGO.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/biocytogen-expands-partnership-with-merck\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/biocytogen-expands-partnership-with-merck\\\/\",\"name\":\"Biocytogen Expands Partnership with Merck - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/biocytogen-expands-partnership-with-merck\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/biocytogen-expands-partnership-with-merck\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220824005289\\\/en\\\/1552165\\\/21\\\/Biocytogen%27s_LOGO.jpg\",\"datePublished\":\"2022-08-25T00:01:36+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/biocytogen-expands-partnership-with-merck\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/biocytogen-expands-partnership-with-merck\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/biocytogen-expands-partnership-with-merck\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220824005289\\\/en\\\/1552165\\\/21\\\/Biocytogen%27s_LOGO.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220824005289\\\/en\\\/1552165\\\/21\\\/Biocytogen%27s_LOGO.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/biocytogen-expands-partnership-with-merck\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Biocytogen Expands Partnership with Merck\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Biocytogen Expands Partnership with Merck - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/biocytogen-expands-partnership-with-merck\/","og_locale":"en_US","og_type":"article","og_title":"Biocytogen Expands Partnership with Merck - Pharma Trend","og_description":"BEIJING & DARMSTADT, Germany–(BUSINESS WIRE)–#License–Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”) entered into a global licensing agreement with Merck for the use of Biocytogen\u2019s RenMice\u2122 platform. Under the terms of the agreement, Merck will have full access to Biocytogen\u2019s RenMice\u2122 platform to discover and develop fully human antibody therapeutics for an unlimited number of drug targets. ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/biocytogen-expands-partnership-with-merck\/","og_site_name":"Pharma Trend","article_published_time":"2022-08-25T00:01:36+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220824005289\/en\/1552165\/21\/Biocytogen%27s_LOGO.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/biocytogen-expands-partnership-with-merck\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/biocytogen-expands-partnership-with-merck\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Biocytogen Expands Partnership with Merck","datePublished":"2022-08-25T00:01:36+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/biocytogen-expands-partnership-with-merck\/"},"wordCount":431,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/biocytogen-expands-partnership-with-merck\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220824005289\/en\/1552165\/21\/Biocytogen%27s_LOGO.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/biocytogen-expands-partnership-with-merck\/","url":"https:\/\/pharma-trend.com\/en\/biocytogen-expands-partnership-with-merck\/","name":"Biocytogen Expands Partnership with Merck - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/biocytogen-expands-partnership-with-merck\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/biocytogen-expands-partnership-with-merck\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220824005289\/en\/1552165\/21\/Biocytogen%27s_LOGO.jpg","datePublished":"2022-08-25T00:01:36+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/biocytogen-expands-partnership-with-merck\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/biocytogen-expands-partnership-with-merck\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/biocytogen-expands-partnership-with-merck\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220824005289\/en\/1552165\/21\/Biocytogen%27s_LOGO.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220824005289\/en\/1552165\/21\/Biocytogen%27s_LOGO.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/biocytogen-expands-partnership-with-merck\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Biocytogen Expands Partnership with Merck"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/47641","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=47641"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/47641\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=47641"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=47641"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=47641"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}